# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Jones Trading analyst Soumit Roy maintains Adicet Bio (NASDAQ:ACET) with a Buy and lowers the price target from $6 to $4.
Canaccord Genuity analyst John Newman maintains Adicet Bio (NASDAQ:ACET) with a Buy and lowers the price target from $19 to $8.
HC Wainwright & Co. analyst Edward White downgrades Adicet Bio (NASDAQ:ACET) from Buy to Neutral.
On September 10, 2024, Adicet Bio, Inc. (the Company or Adicet) announced a strategic prioritization to focus ADI-001 developme...
HC Wainwright & Co. analyst Edward White reiterates Adicet Bio (NASDAQ:ACET) with a Buy and maintains $10 price target.
Canaccord Genuity analyst John Newman maintains Adicet Bio (NASDAQ:ACET) with a Buy and maintains $19 price target.
HC Wainwright & Co. analyst Edward White reiterates Adicet Bio (NASDAQ:ACET) with a Buy and maintains $10 price target.